Article
Pharmacology & Pharmacy
Xiaomin Wan, Xiaohui Zeng, Liubao Peng, Ye Peng, Qiao Liu, Lidan Yi, Xia Luo, Qijian Deng, Chongqing Tan
Summary: The study suggests that nivolumab plus ipilimumab may be more cost-effective compared to chemotherapy, especially at a WTP threshold of $100,000/QALY to $150,000/QALY. Body weight and overall survival hazard ratio are key variables influencing the cost-effectiveness ratio.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Immunology
Yamin Shu, Yiling Ding, Feie Li, Qilin Zhang
Summary: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) in China. The results showed that while nivolumab plus ipilimumab improved overall survival and progression-free survival compared to chemotherapy, it was not cost-effective.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Oncology
Szu-Chun Yang, Natalia Kunst, Cary P. Gross, Jung-Der Wang, Wu-Chou Su, Shi-Yi Wang
Summary: Based on subgroup and probabilistic analysis, researchers found that first-line N+I or N+I+chemotherapy for metastatic NSCLC patients was not cost-effective from the U.S. health care sector perspective, regardless of PD-L1 expression levels.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Kenneth L. Kehl, Scott Greenwald, Nassib G. Chamoun, Paul J. Manberg, Deborah Schrag
Summary: This study investigated treatment patterns and overall survival associated with immunotherapy, chemotherapy, and chemoimmunotherapy in older patients with advanced NSCLC and Medicare coverage. Results showed a rapid uptake of immunotherapy among Medicare-insured patients, but survival estimates were shorter than those reported in registrational trials.
Article
Oncology
H. Borghaei, T. -E. Ciuleanu, J. -S Lee, A. Pluzanski, R. Bernabe Caro, M. Gutierrez, Y. Ohe, M. Nishio, J. Goldman, N. Ready, D. R. Spigel, S. S. Ramalingam, L. G. Paz-Ares, J. F. Gainor, S. Ahmed, M. Reck, M. Maio, K. J. O'Byrne, A. Memaj, F. Nathan, P. Tran, M. D. Hellmann, J. R. Brahmer
Summary: First-line nivolumab plus ipilimumab treatment in advanced NSCLC can prolong survival and have significant clinical benefits, with tumor response affecting survival.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Shixian Liu, Lei Dou, Kaixuan Wang, Zhao Shi, Ruixue Wang, Xiaohong Zhu, Zehua Song, Shunping Li
Summary: This study aimed to assess the cost-effectiveness of nivolumab plus chemotherapy and nivolumab plus ipilimumab compared to chemotherapy as first-line treatment for advanced esophageal squamous-cell carcinoma (ESCC) in China. The results showed that while nivolumab combination therapy improved survival time and health outcomes, it was not considered cost-effective in the Chinese healthcare system.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Xueyan Liang, Xiaoyu Chen, Huijuan Li, Yan Li
Summary: This study assessed the cost-effectiveness of cemiplimab plus chemotherapy compared to chemotherapy alone for the treatment of advanced non-small cell lung cancer (aNSCLC) from the perspective of third-party payers in the United States. The results showed that cemiplimab plus chemotherapy improved efficacy but also increased costs, with an incremental cost-effectiveness ratio (ICER) above the willingness-to-pay (WTP) threshold.
FRONTIERS IN ONCOLOGY
(2023)
Article
Pharmacology & Pharmacy
Tingting Lu, Yufan Huang, Zhongjie Cai, Wangchun Lin, Xiaoxiao Chen, Ruijia Chen, Yingying Hu
Summary: The EMPOWER-LUNG 3 trial demonstrated that cemiplimab plus chemotherapy (CCT) improved overall survival (OS) and progression-free survival (PFS) for patients with advanced non-small cell lung cancer (NSCLC) compared to placebo plus chemotherapy (PCT). However, the cost-effectiveness of this treatment in China is uncertain. Therefore, this study evaluated the cost-effectiveness of CCT as the first-line treatment for advanced NSCLC patients from the perspective of the Chinese healthcare system.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
M. Reck, T. -E. Ciuleanu, M. Cobo, M. Schenker, B. Zurawski, J. Menezes, E. Richardet, J. Bennouna, E. Felip, O. Juan-Vidal, A. Alexandru, H. Sakai, A. Lingua, F. Reyes, P. -J. Souquet, P. De Marchiy, C. Martin, M. Perol, A. Scherpereel, S. Lu, L. Paz-Ares, D. P. Carbone, A. Memaj, S. Marimuthu, X. Zhang, P. Tran, T. John
Summary: The updated data from the phase III CheckMate 9LA trial with a minimum 2-year follow-up show that first-line nivolumab plus ipilimumab with two cycles of chemotherapy continues to provide prolonged overall survival benefits over chemotherapy in advanced non-small-cell lung cancer patients, with manageable safety profile. Improved efficacy outcomes were observed in most subgroups with no new safety signals detected.
Review
Biotechnology & Applied Microbiology
Danilo Rocco, Luigi Della Gravara, Ciro Battiloro, Cesare Gridelli
Summary: The latest breakthrough in advanced Non Small Cell Lung Cancer (NSCLC) treatment is PD-1/PD-L1-targeting Immune Checkpoint Inhibitors (ICIs), which are being evaluated in combination therapies to achieve higher response rates and more durable clinical response. Nivolumab-based combination regimens are expected to become standard treatments for naive advanced NSCLC patients in the near future, but further studies on predictive and prognostic biomarkers are necessary to identify which patients will benefit the most from these regimens. Additionally, research on safer and more durable second-line treatments is also crucial.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2021)
Article
Economics
Munenobu Kashiwa
Summary: This study performed a model-based cost-effectiveness analysis comparing first-line and second-line nivolumab therapy for advanced esophageal cancer to support public healthcare in Japan. The results showed that nivolumab was cost-effective as a first-line therapy in combination with chemotherapy, but not as a second-line monotherapy. Patient selection based on PD-L1 expression may improve the cost-effectiveness of using nivolumab as a first-line treatment.
EUROPEAN JOURNAL OF HEALTH ECONOMICS
(2023)
Article
Oncology
Teja Voruganti, Pamela R. Soulos, Ronac Mamtani, Carolyn J. Presley, Cary P. Gross
Summary: The introduction of immune checkpoint inhibitors has transformed the care of advanced non-small cell lung cancer, but it is unclear how outcomes have changed in clinical practice.
Review
Oncology
Ramon Andrade Bezerra De Mello, Rafael Voscaboinik, Joao Vittor Pires Luciano, Rafaela Vilela Cremonese, Giovanna Araujo Amaral, Pedro Castelo-Branco, Georgios Antoniou
Summary: This paper provides a reliable data source on advanced non-small cell lung cancers without driver mutations and their treatment with immunotherapy. Through a review of the latest research on PD-1/PD-L1 and CTLA-4 inhibitors, the paper presents the current advancements in immunotherapy for this type of lung cancer, particularly the use of PD-1, PD-L1, and CTLA-4 inhibitors. Immunotherapy has transformed the treatment of advanced NSCLC lacking driver mutations, becoming first-line therapy with excellent results. The paper also explores the combination of cytotoxic chemotherapy, VEGF inhibitors, and immunotherapy for patients with low PDL-1 positivity tumors, showing significant improvement in overall survival and progression-free survival.
Article
Multidisciplinary Sciences
J. Capdevila, J. Hernando, A. Teule, C. Lopez, R. Garcia-Carbonero, M. Benavent, A. Custodio, A. Garcia-Alvarez, A. Cubillo, V. Alonso, A. Carmona-Bayonas, T. Alonso-Gordoa, G. Crespo, P. Jimenez-Fonseca, M. Blanco, A. Viudez, A. La Casta, I. Sevilla, A. Segura, M. Llanos, S. Landolfi, P. Nuciforo, J. L. Manzano
Summary: Single immune checkpoint blockade has limited efficacy in patients with NENs. However, dual checkpoint blockade with durvalumab and tremelimumab shows promising results in patients with advanced NENs of gastroenteropancreatic and lung origin. This study highlights the potential of durvalumab plus tremelimumab as a treatment option for NENs patients.
NATURE COMMUNICATIONS
(2023)
Review
Oncology
Maxime Bossageon, Aurelie Swalduz, Christos Chouaid, Olivier Bylicki
Summary: The treatment of metastatic non-small-cell lung cancers (NSCLCs) has traditionally relied on cytotoxic chemotherapy, but the introduction of immune checkpoint inhibitors has revolutionized therapeutic standards. These inhibitors are now the first-line therapy and have shown efficacy in patients with specific expression profiles. Combination therapies of immune checkpoint inhibitors with chemotherapy have demonstrated significant improvements in overall survival, but the use of combination immunotherapies requires further investigation.